Roche is 'e­val­u­at­ing po­ten­tial op­tion­s' for IPF drug Es­bri­et as gener­ics gain trac­tion

Roche is look­ing to of­fload its id­io­path­ic pul­monary fi­bro­sis drug Es­bri­et as more pa­tients with the fa­tal lung dis­ease opt for gener­ic ver­sions and Big Phar­mas con­tin­ue to shed non-core as­sets.

“As part of the nor­mal process to re­view our port­fo­lio of es­tab­lished prod­ucts, we are cur­rent­ly eval­u­at­ing po­ten­tial op­tions for Es­bri­et. This process will take sev­er­al months un­til a fi­nal de­ci­sion is tak­en,” a Roche spokesper­son con­firmed to End­points News via an emailed state­ment on Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER